Search Results - "Stüssi, G."

IN1 Molecular biology of AML by Stüssi, G

Get full text

IN2 Therapeutic strategies of AML by Stüssi, G

Get full text

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome by Janssen, J. J. W. M., Löwenberg, B., Manz, M., Biemond, B. J., Westerweel, P. E., Klein, S. K., Fehr, M., Sinnige, H. A. M., Efthymiou, A., Legdeur, M. C. J. C., Pabst, T., Gregor, M., van der Poel, M. W. M., Deeren, D., Tick, L. W., Jongen-Lavrencic, M., van Obbergh, F., Boersma, R. S., de Weerdt, O., Chalandon, Y., Heim, D., Spertini, O., van Sluis, G., Graux, C., Stüssi, G., van Norden, Y., Ossenkoppele, G. J.

“…Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1…”
Get full text

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME by Frustaci, A. M., Montillo, M., Rossi, D., Zinzani, P. L., Motta, M., Gaidano, G., Quaresmini, G., Scarfò, L., Pietrasanta, D., Coscia, M., Deodato, M., Zamprogna, G., Cairoli, R., Stüssi, G., Zucca, E., Pileri, S., Zenz, T., Tedeschi, A.

Get full text

Combination therapy for multidrug‐resistant cytomegalovirus disease by Stuehler, C., Stüssi, G., Halter, J., Nowakowska, J., Schibli, A., Battegay, M., Dirks, J., Passweg, J., Heim, D., Rovo, A., Kalberer, C., Bucher, C., Weisser, M., Dumoulin, A., Hirsch, H.H., Khanna, N.

“…Multidrug‐resistant (MDR) cytomegalovirus (CMV) emerged after transient responses to ganciclovir, foscarnet, and cidofovir in a CMV‐seropositive recipient who…”
Get full text

P834: REAL‐WORLD EVIDENCE OF SAFETY AND EFFECTIVENESS OF ECULIZUMAB AND SWITCH TO RAVULIZUMAB IN A SWISS PATIENT POPULATION WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA by Rovó, A., Simeon, L., Gavillet, M., Samii, K., Cantoni, N., Heim, D., Stüssi, G., Bissig, M.

Get full text

Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphoma by Pirosa, M. C., Bruscaggin, A., Terzi di Bergamo, L., Salehi, M., Spina, V., Pini, K., Bocchetta, S., Giordano, C., Forestieri, G., Condoluci, A., Piffaretti, D., Almeida, J. Marques, Galimberti, G. A., Annunziata, S., Bergesio, F., Boldorini, R., Borsatti, E., Bulian, P., Chauvie, S., Cuzzocrea, M., di Trani, M., Cristaldi, V., Gerber, B., Jauk, F., Kurlapski, M., Larocca, L. M., Moccia, A., Moia, R., Rinaldi, A., Rodari, M., Romanowicz, G., Sacchetti, G. M., Stathis, A., Stüssi, G., Zangrilli, I., Pinto, A., Mazzucchelli, L., Gattei, V., Zaucha, J. M., Hohaus, S., Santoro, A., Carlo‐Stella, C., Gaidano, G., Cavalli, F., Zucca, E., Ceriani, L., Rossi, D.

Get full text

PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) by Arribas, A, Rinaldi, A, Spriano, F, Tarantelli, C, Gaudio, E, Bernasconi, E, Hillmann, P, Kwee, I, Stathis, A, Fabbro, D, Stüssi, G, Zucca, E, Rossi, D, Cmiljanovic, V, Bertoni, F

“…An abstract of a study by Arribas et al on PQR309, idelalisib, duvelisib and ibrutinib that lead to similar gene expression changes in activated B-cell like…”
Get full text

IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA by Condoluci, A., Terzi‐di‐Bergamo, L., Forestieri, G., Moia, R., Deambrogi, C., Deodato, M., Frustaci, A. M., Merli, M., Mattarucchi, R., Autore, F., Fahrni, G., Scarfò, L., Gussetti, D., Bulian, P., Zanatta, A., Spina, V., Faderl, M. R., Bruscaggin, A., Pini, K., Piffaretti, D., Koch, R., Pirosa, M. C., Cittone, M. G., Passweg, J., Cavalli, F., Zucca, E., Gerber, B., Gillessen, S., Stüssi, G., Gattei, V., Ghia, P., Gregor, M., Laurenti, L., Passamonti, F., Tedeschi, A., Gaidano, G., Rossi, D.

Get full text

CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA by Spina, V., Pirosa, M. C., Bruscaggin, A., Condoluci, A., Pini, K., Forestieri, G., Zangrilli, I., di Trani, M., Kurlapski, M., Moccia, A., Moia, R., Bulian, P., Annunziata, S., Borsatti, E., Rodari, M., Romanowicz, G., Sacchetti, G. M., Faderl, M., Koch, R., Piffaretti, D., Terzi di Bergamo, L., Stasia, A., Cittone, M., Chauvie, S., Stüssi, G., Gerber, B., Stathis, A., Sommer, S. Gillessen, Cavalli, F., Zucca, E., Gattei, V., Zaucha, J. M., Pinto, A., Gaidano, G., Carlo‐Stella, C., Hohaus, S., Ceriani, L., Rossi, D.

Get full text

The Swiss MDS Registry/Biobank: Interim-Report of Pilot Phase from a Cooperative Research Platform for Personalized Medicine in Hemato-Oncology in Switzerland by Bonadies, N, Bacher, V.U, Rovo, A, Bohlius, J, Stüssi, G, Gerber, B, Wilk, C, Balabanov, S, Ruefer, A, Benz, R, Holbro, A, Cantoni, N, Schmid, M, Mengis-Bay, C, Blum, S, Silzle, T, Lehmann, T, Goede, J

Get full text

INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS‐A) by Condoluci, A., Terzi di Bergamo, L., Langerbeins, P., Hoechstetter, M., Herling, C., De Paoli, L., Delgado, J., Gentile, M., Doubek, M., Mauro, F.R., Chiodin, G., Mattsson, M., Bahlo, J., Cutrona, G., Kotaskova, J., Deambrogi, C., Moia, R., Gerber, B., Zucca, E., Ghielmini, M., Cavalli, F., Stüssi, G., Neri, A., Ferrarini, M., Rosenquist, R., Forconi, F., Foà, R., Pospisilova, S., Morabito, F., Wierda, W.G., Montserrat, E., Gaidano, G., Hallek, M., Rossi, D.

Get full text

S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA by Pirosa, M. C., Bruscaggin, A., Terzi di Bergamo, L., Salehi, M., Pini, K., Spina, V., Bocchetta, S., Condoluci, A., Forestieri, G., Piffaretti, D., Marques De Almeida, J., Annunziata, S., Bergesio, F., Borsatti, E., Bulian, P., Chauvie, S., Marco, C., Martina, D. T., Bernhard, G., Kurlapski, M., Moccia, A., Moia, R., Rinaldi, A., Rodari, M., Romanowicz, G., Sacchetti, G. M., Stasia, A., Stathis, A., Stüssi, G., Zangrilli, I., Larocca, L. M., Pinto, A., Santoro, A., Cavalli, F., Zucca, E., Gattei, V., Zaucha, J. M., Carlo‐Stella, C., Hohaus, S., Gaidano, G., Ceriani, L., Rossi, D.

Get full text

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy by Bruscaggin, A., Spina, V., Di Trani, M., Martini, M., Locatelli, S., Cupelli, E., Forestieri, G., Condoluci, A., Cuccaro, A., Moccia, A., Stathis, A., Manzoni, M., Deambrogi, C., Diop, F., Stüssi, G., Cavalli, F., Bertoni, F., Zucca, E., Larocca, L.M., Gaidano, G., Hohaus, S., Carlo‐Stella, C., Rossi, D.

Get full text

Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia by Heim, D, Friess, D, Christen, S, Stüssi, G, Meyer-Monard, S, Tichelli, A, Passweg, J R, Gratwohl, A

Get full text

Risk factors for ICU admission and ICU survival after allogeneic hematopoietic SCT by Benz, R, Schanz, U, Maggiorini, M, Seebach, J D, Stussi, G

“…A considerable number of patients undergoing allogeneic hematopoietic SCT (HSCT) develop post-transplant complications requiring intensive care unit (ICU)…”
Get full text

Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience by Samaras, Panagiotis, Blickenstorfer, Marcel, Haile, Sarah R, Siciliano, Raffaele Daniele, Petrausch, Ulf, Mischo, Axel, Zweifel, Martin, Honegger, Hanspeter, Schanz, Urs, Stussi, Georg, Taverna, Christian, Bauer, Stefan, Knuth, Alexander, Stenner-Liewen, Frank, Renner, Christoph

“…High-dose chemotherapy with subsequent autologous stem cell transplantation (ASCT) is an important treatment option in younger patients with multiple myeloma…”
Get full text

Sideroblastic changes of the bone marrow can be predicted by the erythrogram of peripheral blood by ROVÓ, A., STÜSSI, G., MEYER-MONARD, S., FAVRE, G., TSAKIRIS, D., HEIM, D., HALTER, J., ARBER, C., PASSWEG, J., GRATWOHL, A., TICHELLI, A.

“…Summary The diagnosis of sideroblastic anemia is based on bone marrow aspiration, and the detection of ring sideroblasts (RS) in iron staining. The finding of…”
Get full text

Reply to Canet et al: Acute kidney injury in critically ill allo-HSCT recipients by Benz, R, Stussi, G

Get full text

IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R‐CHOP by Arribas, A., Napoli, S., Cascione, L., Sartori, G., Cannas, E., Tarantelli, C., Spriano, F., Gaudio, E., Zucchetto, A., Rossi, F. M., Rinaldi, A., Castro de Moura, M., Jovic, S., Pittau, R. Bordone, Stathis, A., Stussi, G., Gattei, V., Brown, J. R., Esteller, M., Zucca, E., Rossi, D., Bertoni, F.

Get full text